NEW YORK, November 3, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will disclose updated interim safety and efficacy data from its ongoing REP 301 trial (NCT02233075) at the 2015 meeting of the American Association for the Study of Liver Disease (AASLD) being held from November 13-17 in San Francisco, USA. Updated data from the REP 301 trial is scheduled to be presented (Abstract 31) on Sunday November 15th in Parallel Session 4: Hepatitis B: Novel Treatments and Treatment Targets
The REP 301 trial is examining the safety and efficacy of REP 2139-Ca monotherapy, followed by combined therapy with pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection. Interim data previously presented from the REP 2139-Ca monotherapy phase of the trial demonstrated that REP 2139-Ca was well tolerated and resulted in the rapid and simultaneous multi-log reduction of both serum HBsAg (up to 6 logs) and HDV RNA (up to 7 logs) with many patients having no detectable serum HBsAg or HDV RNA after 15 weeks. Updated data will cover the combination therapy portion of the protocol, when pegylated interferon alpha 2a is added to patient’s existing REP 2139-Ca regimen.
For the AASLD 2015 meeting:
For the AASLD 2015 abstract book:
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com or follow us on Twitter @replicorinc.